tradingkey.logo

Sionna Therapeutics Announces Positive Phase 1 Data For Nbd1 Stabilizers Sion-719 And Sion-451 And Advances Both Programs In Clinical Development For Cystic Fibrosis

ReutersJun 4, 2025 11:16 AM

Sionna Therapeutics Inc SION.O:

  • SIONNA THERAPEUTICS ANNOUNCES POSITIVE PHASE 1 DATA FOR NBD1 STABILIZERS SION-719 AND SION-451 AND ADVANCES BOTH PROGRAMS IN CLINICAL DEVELOPMENT FOR CYSTIC FIBROSIS

  • SIONNA THERAPEUTICS INC -NEXT TRIALS TO INITIATE IN SECOND HALF OF 2025 WITH TOPLINE DATA EXPECTED IN MID-2026

  • SIONNA THERAPEUTICS- SION-719 AND SION-451 WERE GENERALLY WELL TOLERATED AND ACHIEVED DESIRED PHARMACOKINETIC TARGETS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI